Locations:
Search IconSearch
April 29, 2021/Cancer

Early Pelvic Drain Removal Does Not Increase Infection Risk

Challenging an old surgical standard

18-DDI-5519-Rectal-Cancer-Hero-Image-650x450pxl

The early removal of pelvic drains following abdominoperineal resection (APR) for rectal cancer is not associated with increased pelvic or perineal surgical site infections (SSI), according to a retrospective study presented at the American Society of Colon & Rectal Surgeons 2021 Annual Scientific Meeting. This finding challenges the longstanding surgical dogma that leaving pelvic drains helps prevent SSI or perineal wound complications after APR and encourages further prospective trials investigating the omission of pelvic drains following APR.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Recently, prospective trials have shown that pelvic drains are not helpful in the context of low anterior resection for rectal cancer,” says David Liska, MD, Director of the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia at Cleveland Clinic’s Digestive Disease & Surgery Institute and senior author of the study. “And yet, most surgeons still use them, hoping to reduce pelvic fluid collection and infection, or perineal wound complications but with no data supporting their use.”

Currently, timing of drain removal varies widely and is sometimes guided by arbitrary levels of drainage volume. Enhanced recovery protocols (ERP) call for avoiding drains or removing them early to accelerate recovery and patient discharge.

Morbidity increases with drain time

Researchers reviewed all rectal cancer patients treated with APR at Cleveland Clinic from 2009 to 2017 and tracked preoperative patient factors, operative details and 30-day outcomes. They separated patients whose pelvic drains were removed after volume decreased to < 150 mL and those with drain removal with output ≥ 150 mL.

Of 139 patients included, 53 had drain volume ≥ 150 mL on the day preceding removal, and 86 had removal following a volume decrease below < 150 mL. The high-volume removal group had pelvic drains removed earlier (median 4 days vs. 6 days, P < 0.001) than the group with lower drain volume upon removal. They also more frequently had minimally invasive surgery (69.8% vs. 31.4%, P < 0.001) and were more often treated within the context of an ERP (39.6% vs. 15.1%, P = 0.002).

Advertisement

The early drain removal group had lower overall morbidity (43.4% vs. 67.4%, P = 0.009) and incisional SSI (7.55% vs. 22.1%, P = 0.045). Researchers found no significant difference in pelvic and/or perineal SSI between the groups (11.3% vs. 22.1%, P = 0.168). When controlling for differences in the use of minimally invasive surgery and ERP, early drain removal was not associated with increased pelvic or perineal SSI.

“Instead, we found that delaying drain removal was actually associated with an increase in morbidity,” says Dr. Liska (RR = 1.48, P < 0.001).

Deconstructing the dogma

These results are in line with findings of recent prospective trials that pelvic drains after low anterior resection for rectal cancer are not of benefit to the patient. “We demonstrated that removing the drains sooner, regardless of drainage volume, confers no disadvantage,” says Dr. Liska. “These findings lay the groundwork for future prospective trials and get us one step closer to deconstructing the surgical dogma of routinely using pelvic drains after abdominoperineal resections for patients with rectal cancer.”

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad